30results about "Intestine cancer vaccine" patented technology

The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

The invention discloses a chimeric antigen receptor of a cell for targeted expression of Claudin 18.2 (CLDN 18.2), and particularly discloses a chimeric antigen receptor with an amino acid sequence as shown in SEQ ID NO.14. The chimeric antigen receptor comprises a Claudin 18.2-targeted single-chain antibody, a hinge region, a transmembrane structural domain and an intracellular signal structural domain. The Claudin 18.2-targeted chimeric antigen receptor disclosed by the invention can achieve effective and specific targeted expression of malignant cells (such as tumor cells) of the Claudin 18.2 surface antigen, so that a more efficient method with fewer side effects and adverse reactions is provided for treating some tumors expressing the Claudin 18.2 surface antigen.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to formulations comprising an anti-PD-L1/OX40 bispecific antibody, in particular to pharmaceutical formulations comprising an anti-PD-L1/OX40 bispecific antibody, a buffer, a stabilizer and a surfactant. In addition, the invention also relates to the use of these formulations for the treatment or prevention of diseases.

The invention belongs to the technical field of cellular immune biology, and particularly relates to application of PLPP1 in preparation of a T cell immune tumor related medicament. The PLPP1 is a keyenzyme for regulating and controlling T cell phospholipid metabolism; in a tumor microenvironment, the reduction of the expression of the metabolism key enzyme PLPP1 causes abnormal CD8+ T cell phospholipid metabolism, then causes abnormal CD8+ T cell metabolism, and finally causes abnormal T cell functions; and that is, the expression of the PLPP1 has a positive correlation relationship with activation, infiltration and functions of CD8+ T cells in the tumor microenvironment. In-depth studies show that after a PDL1/ PD-1 signal path is activated, an AKT/ mTOR signal path is further activated, the expression of the T cell phospholipid metabolism key enzyme PLPP1 is regulated and controlled by a transcription factor GATA1, and finally the T cell function adjustment is achieved by the change of the T cell metabolism function.

The invention relates to a specific chimeric antigen receptor cell armed with a targeted CXCR2 ligand as well as a preparation method and application thereof. Through a method, which uses a recombinant carrier of a chimeric antigen receptor that specifically targets human NKG2DL armed with a targeting CXCR2 ligand to modify a immune response cell, the obtained novel functionalized immune responsecell can effectively attack multiple tumors in a targeted mode; and the functionalized immune response cell can be used to prepare preparations for treating malignant tumors. The engineering immune cells modified by a chimeric antigen receptor that is armed with a targeting CXCR2 ligand and specifically targets human NKG2DL can more easily migrate to a tumor position and continuously kill the tumors in a targeted mode.

Compositions and treatments for inducing tumor regression by activating inflammasomes in tumor cells and tumor-associated cells. A tumor in a subject is treated by administering a composition to the subject that activates inflammasomes in cells of the tumor and thereby causes tumor cell pyroptosis and tumor regression.

The invention relates to the field of cancer, in particular kidney cancer. In particular, it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the BAP, PBRM1, SETD2, and VHL genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

The present disclosure provides the gene therapy compositions comprising vectors (e.g., viral vectors) suitable for delivery of nucleic acids encoding immunomodulatory proteins or functional fragments thereof, and methods of using the same. Certain aspects of the disclosure are directed to an adeno-viral vector (AAV) delivery of nucleic acids encoding two or more immunomodulatory proteins or functional fragments thereof to a tumor.

The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering a mixed population of T cells comprising modified T cells comprising a first chimeric antigen receptor (CAR) and modified T cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

The invention discloses an encoding gene of an anti-EpCAM chimeric antigen receptor, a preparation method of the encoding gene, a plasmid with the gene, an immune cell and an application of the encoding gene, wherein the encoding gene at least comprises an EpCAM binding region and a CTLA4 binding region and also comprises a T2A nucleic acid artificial sequence located between the EpCAM binding region and the CTLA4 binding region, and the encoding gene of the anti-EpCAM chimeric antigen receptor further comprises a transmembrane-stimulation structural domain; the transmembrane-stimulation structural domain is selected from all or part of fragments of CD8, CD27, CD28, CD226, 4-1BB, OX40 and ICOS molecules. The encoding gene of the anti-EpCAM chimeric antigen receptor provided by the invention enhances the killing effect of T cells on tumor cells.

The invention provides a chimeric antigen receptor (CAR) modified T cell capable of secreting TLR4 scFv and targeting cMet as well as application of the T cell. The T cell contains a coding sequence of a CAR recognizing cMet and a coding sequence of a TLR4 scFv antibody secreting a signal peptide. The CAR modified T cell can be activated while specifically targeting tumor cells with high expression of cMet, secret the TLR4 scFv antibody, weaken the immunosuppressive action of a tumor microenvironment, reduce expression of Treg cells and promote the killing effect of CD8<+>T cells on tumor.

The present invention discloses a combined pharmaceutical preparation for treating melanoma, lung cancers or colorectal cancers. The pharmaceutical preparation comprises an effective amount of an antibody of a programmed death receptor ligand 1 (PD-L1) and cilengitide. The combined pharmaceutical preparation combines the integrin inhibitor cilengitide and the PD-L1 inhibitor to inhibit tumor cellproliferation while inhibiting formation of new blood vessels in a tumor microenvironment and enhancing infiltration and activation of T cells to improve an immune microenvironment. Compared with single drug use, the inhibition effects of the cilengitide and PD-L1 inhibitors are relatively clear, side effects are relatively low, and risks are relatively low. After the combined use, an objective remission rate of the tumors is higher than that of the single drug use, total survival time is increased and no lethal side effects are observed.